Based upon a successful engagement with the US Food and Drug Administration (FDA) at the End-of-Phase 2 meeting in January 2025, Atea is initiating a global Phase 3 program and expects patient ...

Switching to islatravir and doravirine was just as effective as bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC ...

Hepatitis B virus infection remains one of the leading causes of liver disease, including cirrhosis and hepatocellular carcinoma.

The US joins Moldova, Hong Kong, and New Zealand as countries to greenlight the company's Phase I trial of PBGENE-HBV.

Chronic hepatitis B virus (HBV) infection continues to pose a major global health threat. The virus evades immune responses and antiviral therapies due to the persistence of covalently closed circular ...

Explore diffuse large B-cell lymphoma — symptoms, causes, diagnosis, treatment options, and prevention. Learn about its types ...

The programme includes the ECLIPSE 1 and ECLIPSE 2 Phase III trials, aiming to offer registrational data for regulatory submissions.

Hepatitis B can lead to liver disease. But we can prevent and manage this viral infection. Here’s what we know about the ...

Infections with the hepatitis E virus often go unnoticed because they cause no symptoms. However, in patients with a weakened ...

Identify the warning signs of hepatitis before they become serious. From subtle fatigue to more obvious symptoms, recognizing liver inflammation early can save.

A more affordable, lower-risk polio vaccine is on the horizon, research led by the University of Leeds has found.

Several studies have suggested that COVID-19 may increase a person’s risk of developing cancer or promote metastasis of existing cancer.